Active Implants

"Active Implants has commercialized two unique orthopedic implants in Europe with a visible pathway to bring them into the U.S.," Matson noted in his report. "In particular, it [is] seeking FDA approval of its NUsurface Meniscus Implant which is the first 'artificial meniscus' and intended to fill the gap between minimally invasive meniscus repair and total knee replacement."

In the United States, Active Implants has enrolled two clinical trials and Mills' report puts the total addressable U.S. market at about $5 billion.